Organogels based on amino acid derivatives and their optimization for drug release using response surface methodology
Source abstract
Abstract
Organogels are excellent drug carrier for controlled release. Organogels based on amino acid derivatives has been widely used in the area of drug delivery. In this study, a series of the organogel system based on amino acid derivatives gelators was designed and prepared to investigate the structure-property correlation in organogels. To investigate the factors that influence the property of drug release, we varied the formulation in the organogels: gelator structure, gelator concentration, volume of antigelation solvent, and drug loading. Through the Box-Behnken tests, the optimum organogel formulation in vitro was obtained. The self-healing properties of the organogel have been utilised for injection of a model lipophilic risperidone in situ, and sustained release of the drug has been studied over about one week in vivo. In conclusion, the gelation ability of gelators could be adjusted by the gelator structure. Gel property is related with the whole composition of the formulation. As drug carrier, the drug release property of organogels is affected by multiple factors. Our investigation of the gel release property will play a theoretical guiding role in the application in the in situ drug delivery system.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Supramolecular Self-Assembly in Materials · Glycosylation and Glycoproteins Research · Lipid Membrane Structure and Behavior
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology
School of Mechanical Engineering, Hebei University of Science and Technology
School of Pharmacy, Shenyang Pharmaceutical University
School of Pharmacy, China Medical University
References (36)
Show source-provided references
1. 10.1016/j.colsurfa.2011.05.02710.1016/j.colsurfa.2011.05.027 ↗
2. 10.1039/C4SM02423K10.1039/C4SM02423K ↗
3. 10.1016/j.ejps.2018.10.01310.1016/j.ejps.2018.10.013 ↗
4. 10.1208/s12249-014-0223-710.1208/s12249-014-0223-7 ↗
5. 10.1002/app.3750610.1002/app.37506 ↗
6. 10.1007/s10971-014-3386-510.1007/s10971-014-3386-5 ↗
7. 10.1080/10610278.2013.87713810.1080/10610278.2013.877138 ↗
8. 10.1016/j.ejps.2014.04.02010.1016/j.ejps.2014.04.020 ↗
9. 10.1080/1539445X.2012.75601610.1080/1539445X.2012.756016 ↗
10. 10.1186/1556-276X-8-16010.1186/1556-276X-8-160 ↗
11. 10.1080/10610278.2014.91462810.1080/10610278.2014.914628 ↗
12. 10.1016/j.ejps.2018.12.00910.1016/j.ejps.2018.12.009 ↗
13. 10.3109/03639045.2010.48869410.3109/03639045.2010.488694 ↗
14. 10.1039/c0sm01293a10.1039/c0sm01293a ↗
15. 10.1016/j.biomaterials.2010.04.00910.1016/j.biomaterials.2010.04.009 ↗
16. 10.1007/s11095-007-9384-310.1007/s11095-007-9384-3 ↗
17. 10.1002/adhm.20130062710.1002/adhm.201300627 ↗
18. 10.1080/21691401.2019.157878410.1080/21691401.2019.1578784 ↗
19. 10.1016/S0168-3659(02)00008-110.1016/S0168-3659(02)00008-1 ↗
20. 10.1016/j.colsurfb.2019.01.00310.1016/j.colsurfb.2019.01.003 ↗
21. 10.1080/21691401.2018.143069510.1080/21691401.2018.1430695 ↗
22. 10.3109/03639045.2012.66592810.3109/03639045.2012.665928 ↗
23. 10.1039/C4RA06130F10.1039/C4RA06130F ↗
24. 10.1016/j.biomaterials.2015.06.00810.1016/j.biomaterials.2015.06.008 ↗
25. 10.1016/j.jddst.2018.06.00110.1016/j.jddst.2018.06.001 ↗
26. 10.1016/j.ijbiomac.2015.12.02810.1016/j.ijbiomac.2015.12.028 ↗
27. 10.1016/j.actbio.2017.03.00710.1016/j.actbio.2017.03.007 ↗
28. 10.1016/j.colsurfb.2018.09.02310.1016/j.colsurfb.2018.09.023 ↗
29. 10.1016/j.msec.2017.08.06510.1016/j.msec.2017.08.065 ↗
30. 10.3109/03639045.2016.117133310.3109/03639045.2016.1171333 ↗
31. 10.3109/10717544.2016.115784110.3109/10717544.2016.1157841 ↗
32. 10.1016/j.ijpharm.2018.06.04310.1016/j.ijpharm.2018.06.043 ↗
33. 10.1080/21691401.2019.158179210.1080/21691401.2019.1581792 ↗
34. USP. Semisolid drug products–performance tests. USP 37/NF 32. Rockville, USA: The United States Pharmacopeial Convention; 2014. p. 1273–1284.
35. 10.1016/j.carbpol.2018.07.05410.1016/j.carbpol.2018.07.054 ↗
36. 10.1016/j.msec.2018.06.02210.1016/j.msec.2018.06.022 ↗